Logan Coy Related postsRandomized, open-label study of the BRIA-IMT regimen and checkpoint inhibitor vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC)September 10, 2026A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation Study of Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory Small Cell Lung CancerSeptember 11, 2026A Phase 1/2a, Multicenter, Open-Label, First-in-Human Study of DB-1311 in Advanced/Metastatic Solid TumorsSeptember 11, 2026 Previous postA Phase 1/2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Advanced CancerNext postA Phase 1/2a, Multicenter, Open-Label, First-in-Human Study of DB-1311 in Advanced/Metastatic Solid Tumors